Induction of P450 3A1/2 and 2C6 by gemfibrozil in Sprague-Dawley rats

Pharmacological Reports

Volumn 63, Issue 1, 2011, Pages 157-164

  Liu, Aiming ^a   Yang, Julin ^b   Zhao, Xin ^a   Jiao, Xiaolan ^a   Zhao, Weihong ^a   Ma, Qing ^a   Tang, Zhiyuan ^a   Dai, Renke ^c  

^a NINGBO UNIVERSITY   (China)

^b Ningbo College of Health Sciences   (China)

^c SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Gemfibrozil; Induction; P450; Rat

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; BEZAFIBRATE; CYTOCHROME P450 2C; CYTOCHROME P450 2C6; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; DEXTROMETHORPHAN; DEXTRORPHAN; DICLOFENAC; FLUFENAMIC ACID; GEMFIBROZIL; PROPRANOLOL; TRIAZOLAM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME SUBSTRATE; IN VIVO STUDY; LIVER MICROSOME; NONHUMAN; RAT; SPRAGUE DAWLEY RAT;

EID: 79953194857     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70410-8     Document Type: Article

References (25)

1. Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ: Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther, 2000, 68, 122-129. (Pubitemid 30659167)
2. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ: Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther, 2002, 72, 685-691. (Pubitemid 36021007)
3. Barbier O, Duran-Sandoval D, Pineda-Torra I, Kosykh V, Fruchart JC, Staels B: Peroxisome proliferator-activated receptor α induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J Biol Chem, 2003, 278, 32852-32860. (Pubitemid 37055727)
4. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ et al.: HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med, 2007, 357, 1301-1310. (Pubitemid 47481452)
5. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, Biswas C et al.: Novel peroxisome proliferator-activated receptor (PPAR) γ and PPARδ ligands produce distinct biological effects. J Biol Chem, 1999, 274, 6718-6725. (Pubitemid 29111093)
6. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH et al.: Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA, 2004, 292, 2585-2590. (Pubitemid 39577514)
7. Hoivik DJ, Qualls CW, Jr., Mirabile RC, Cariello NF, Kimbrough CL, Colton HM, Anderson SP et al.: Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys. Carcinogenesis, 2004, 25, 1757-1769. (Pubitemid 39214319)
8. Jacobson TA, Zimmerman FH: Fibrates in combination with statins in the management of dyslipidemia. J Clin Hypertens (Greenwich), 2006, 8, 35-41; quiz 42-43.
9. Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, DeLuca JG et al.: PPARα agonistinduced rodent tumors: modes of action and human relevance. Crit Rev Toxicol, 2003, 33, 655-780. (Pubitemid 38037444)
10. Kobayashi K, Urashima K, Shimada N, Chiba K: Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. Biochem Pharmacol, 2002, 63, 889-896. (Pubitemid 34243002)
11. Krysiak R, Łabuzek K, Okopień B: Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects. Pharmacol Rep, 2009, 61, 1134-1145.
12. Krysiak R, Stachura-Kułach A, Okopień B: Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances. Pharmacol Rep, 2010, 62, 120-130.
13. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ: Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther, 2003, 73, 538-544. (Pubitemid 37249124)
14. Liu A, Xie S, Sun H, Gonzalez FJ, Wei X, Dai R: Myotoxicity of gemfibrozil in cynomolgus monkey model and its relationship to pharmacokinetic properties. Toxicol Appl Pharmacol, 2009, 235, 287-295.
15. Mei L, Zhang L, Dai R: An inhibition study of beauvericin on human and rat cytochrome P450 enzymes and its pharmacokinetics in rats. J Enzyme Inhib Med Chem, 2009, 24, 753-762.
16. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A: Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos, 2006, 34, 191-197. (Pubitemid 43042661)
17. Plasterer T, Hamano T, Damian D, Okada M, Jahasz P, Shimizu T, Zeng C et al.: Biological pathways and plasma biomarkers for muscle toxicity induced by a PPARα agonist, fenofibrate. Toxicol Lett, 2007, 172, 1, S54.
18. Prueksaritanont T, Richards KM, Qiu Y, Strong-Basalyga K, Miller A, Li C, Eisenhandler R, Carlini EJ: Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm Res, 2005, 22, 71-78. (Pubitemid 40558148)
19. Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, Liu L et al.: Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther, 2002, 301, 1042-1051. (Pubitemid 34595097)
20. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC et al.: The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther, 2004, 75, 455-463. (Pubitemid 38534566)
21. Shitara Y, Hirano M, Sato H, Sugiyama Y: Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)- mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther, 2004, 311, 228-236. (Pubitemid 39287802)
22. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y: Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther, 2003, 304, 610-616. (Pubitemid 36152336)
23. Staffa JA, Chang J, Green L: Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med, 2002, 346, 539-540.
24. Yao M, Zhu M, Sinz MW, Zhang H, Humphreys WG, Rodrigues AD, Dai R: Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis. J Pharm Biomed Anal, 2007, 44, 211-223. (Pubitemid 46551606)
25. Zuber R, Anzenbacherova E, Anzenbacher P: Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med, 2002, 6, 189-198. (Pubitemid 44137197)